Middle East and Africa Protein Binding Assay Market

Market Introduction

The MEA protein binding assay market has been further segmented into the UAE, Saudi Arabia, South Africa, and rest of middle east and Africa. The market for protein binding assay in the MEA is anticipated to grow at a CAGR 9.3% during the forecast period; this growth is attributed to increase in pharmaceutical R&D expenditure, increase in developments in the pharmaceutical and biotechnological industries, and the increasing focus on suppressing the expenditure being incurred on the drug discovery & their manufacturing and the availability of various advanced technologies utilized for protein binding. In recent times, protein binding assay holds a promising future as pharmaceutical firms. Saudi Arabia is a very important country in the field of clinical research and the CRO. The health care system is strongly developed. Now more sponsors are developing their medical and research team in the Kingdom. Clinical research has been covered and regulated by the Saudi FDA (SFDA) since 2010, and start-up time tends to decrease even more. The bio/pharmaceutical outsourcing industry has seen an increase in R&D demand as a result of the COVID-19 pandemic. This increase in demand, as well as other pandemic impacts, such as increasing demand for clinical trials and outsourcing services, have led some CROs to shift focus and adjust their operations. The pandemic has pushed more pharmaceutical companies and regulators to use new technologies for remote quality audits and inspections, thus driving positive changes in the pharma industry. The growing pharmaceutical R&D activities in the region boost the adoption of protein binding assays in drug discovery & development likely to drive the market growth

As per Worldometer data, South Africa (2,408,525), Israel (868,045), the UAE (676,251), and Saudi Arabia (522,108) are among the worst-affected countries by the COVID-19 disease in the Middle East and Africa, as of July 2021. The pandemic has boosted the demand for medical devices that can be used in a home care setting. There has been a rise in numbers of patients admitted to intensive care units (ICU), and medications imposing multiple diagnostic and therapeutic challenges on stressed healthcare systems, which has led to a rise in demand for medical devices. According to the World Bank forecasts, remittances to the MENA region are projected to fall sharply by 19.6%, after total of USD 42 billion in 2020 with a 2.6% increase in 2019. For the first time in decades, MENA countries are facing a common issue with no political or religious agenda. The advent of high-throughput screening of approved compounds and small molecules has allowed researchers to effectively evaluate large drug libraries for checking their in vitro antiviral activity against novel targets. Russia has developed a new treatment for COVID-19 patients and is soon going to conduct trial in partnership with Saudi Arabian health. Thus, such increased research and development activities boost the adoption of protein binding assays in drug discovery and development in the Middle East and Africa.

Middle East and Africa Protein Binding Assay Strategic Insights

Strategic insights for the Middle East and Africa Protein Binding Assay provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East and Africa Protein Binding Assay Report Scope

Middle East and Africa Protein Binding Assay Regional Insights

The geographic scope of the Middle East and Africa Protein Binding Assay refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The protein binding assay market in MEA is expected to grow from US$ 16.41 million in 2021 to US$ 30.64 million by 2028; it is estimated to grow at a CAGR of 9.3% from 2021 to 2028. Growing Label- Surge in CRO Industry in emerging markets; contract research organizations (CROs) have rapidly emerged as a force in drug development and clinical trial recruiting. emerging countries are emerging as attractive outsourcing locations for drug manufacturers. Low manufacturing and operating costs are driving the growth of the CRO industry. Recent growth in the pharmaceutical industry indicates a positive outlook for protein binding assay market. The CRO industry is experiencing strong growth owing to surging technological innovations, changing regulations, and increasing outsourcing levels. There is a continuous growth in scientific base and capabilities owing to the growing contribution of clinical research, centralized healthcare institutions, well-qualified and highly motivated investigators, and excellent clinical trial facilities.

Key Market Segments

Based on technology is segmented into ultracentrifugation ultrafiltration, equilibrium dialysis, surface plasmon and others. In 2020, the equilibrium dialysis segment is likely to hold the largest share of the market, by technology. Based on the end user was segmented into contract research organization, pharmaceutical & biotechnology companies, and research & diagnostic laboratories. In 202

0,

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the protein binding assay market in MEA are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Biotium, Inc, Eurofins Scientific, General Electric Company, MERCK KGaA, MicroConstants, Inc, Ltd, Sartorius AG, SOVICELL GMBH, and THERMO FISHER SCIENTIFIC INC. among others.

Reasons to buy report

• To understand the MEA protein binding assay market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for MEA protein binding assay market
• Efficiently plan M&A and partnership deals in MEA protein binding assay market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form MEA protein binding assay market
• Obtain market revenue forecast for market by various segments from 2021-2028 in MEA region.

MEA PROTEIN BINDING ASSAY MARKET SEGMENTATION

By Technology

• Equilibrium Dialysis
• Ultracentrifugation
• Ultrafiltration
• Surface Plasmon
• Others

By

End User

• Contract Research Organization
• Pharmaceutical and Biotechnology Companies
• Research and Diagnostic Laboratories

By Country

• Saudi Arabia
• South Africa
• UAE
• Rest of MEA

Company Profiles

• Biotium, Inc
• Eurofins Scientific
• General Electric Company
• MERCK KGaA
• MicroConstants, Inc
• Sartorius AG
• SOVICELL GMBH
• THERMO FISHER SCIENTIFIC INC.